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Molecular imaging and targeted radiotherapy are emerging fields for cancer treatment. 
DOTA-Tyr (3)-Thr(9)-octreotate (DOTA-TATE) is used for peptide receptor-mediated 
radionuclide therapy (PRMRT) in neuroendocrine tumours. These biomolecules can be 
radiolabeled with an appropriated radioisotope to produce radiopharmaceuticals for 
diagnostic and therapeutic applications. The DOTA-TATE molecule is comprised of a 
bifunctional chelate (DOTA) that is capable of stably binding a radiolanthanide as well as 
being covalently attached to a targeting biomolecule (e.g.,octreotate). Among the 
radiolanthanides, Ho-166, Tb-161 and Lu-177, that were used to label the peptide, Lu-177 
was used to obtain optimum conditions. Direct neutron capture on Lu-176 produces Lu-177. 
The indirect production of Lu-177 proceeds by neutron capture on Yb-176 producing Yb-177, 
which beta decays to Lu-177. Chromatographic separation yields high specific activity Lu-
177 that minimizes the presence of cold Lu-176. Lanthanides have similar chemical 
properties that allow further studies to apply similar conditions as those developed for Lu-
177. In addition, longevity of half-life of Lu-177 enables longer periods of dose delivery to 
targeted tumors. This research focused on identifying appropriate buffer solutions and 
volumes that could neutralize the acidic radioisotope to appropriate pH levels to label the 
peptide in high yield. The sample was purified from the unlabeled peptide by using HPLC 
separations methods and adding stabilizing agents (ascorbic and gentisic acid) to prevent 
radiolysis of the radiolabeled peptide. The results for the labeled peptide with various 
radioisotopes shows that 0.4 M NH4OAc, 0.4 M NaOAc, and 0.01 M HEPES buffer solution 
in 500 µL yields 99% labeling at pH ranging from 6.0 to 7.5. The labeled ligand at equimolar 
ratio with the metal yields 3 mCi/µg of the ligand, whereas as high specific activity sample 
can label up to 6.68 mCi/µg of the ligand. Carrier free Lu-177-DOTA-TATE was labeled 
using 0.01 M HEPES buffer at pH 6.0 and remains stable after using ascorbic acid; gentisic 
acid shows interference on HPLC which may cause some purification problems. (Ho- 
holmium, Tb- terbium Lu- lutetium)
 
